CRTX News and Press, Cortexyme Inc. From 12/07/19

– In a Phase 1b trial, COR388 reduced levels of fragmented ApoE protein in cerebrospinal fluid of subjects with Alzheimer’s – –The drug’s target, the gingipains from P. gingivalis bacteria, preferentially attack the protein encoded by an APOE genetic va...

Gainers:  Kodiak Sciences (NASDAQ: KOD )  +70% . More news on: Kodiak Sciences Inc., ASLAN Pharmaceuticals Limited, Cortexyme, Inc., Stocks on the move, Read more ...

Thinly traded Cortexyme ( CRTX +27.3% ) is up on triple normal volume, albeit on turnover of only 177K shares, ahead of tomorrow's fireside chat by CEO Casey Lynch at Evercore ISI's HealthCONx Conference in Boston at 2 pm ET. More news on: Cortexyme, Inc., Healthcare stocks news, Stocks ...

-- Presentation to be webcast on Cortexyme’s website -- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s and other deg...

Cortexyme (NASDAQ: CRTX ): Q3 GAAP EPS of -$0.37 in-line. Cash and cash equivalents of $44.74M Press Release More news on: Cortexyme, Inc., Earnings news and commentary, Healthcare stocks news,

— Lead investigational medicine COR388, a potentially transformative new paradigm for addressing Alzheimer’s disease, continues to advance in Phase 2/3 GAIN clinical trial — Following successful May 2019 initial public offering, Cortexyme is well capitalized and fo...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

- Presentation will detail impact of Cortexyme’s lead compound, COR388, on ApoE in Alzheimer’s Disease patients - CTAD attendees are also invited to educational session focused on Cortexyme’s new investigational approach to AD treatment Cortexyme, Inc. (Nasdaq...

Cortexyme ( CRTX -1.7% ) commences patient screening in Europe for its Phase 2/3 GAIN  study evaluating lead candidate COR388 for the potential treatment of mild-to-moderate Alzheimer's disease. More news on: Cortexyme, Inc., Healthcare stocks news, Read more ...